Amgen (AMGN) Tops Q2 EPS by 38c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Mahindra & Mahindra Ltd (MM:IN) (MAHMF) PT Raised to INR320 at HSBC
- HSBC Downgrades Shriram Finance Ltd (SHFL:IN) to Hold
- Lockheed Martin to acquire Ultra Maritime for $3.45 billion
- Strategy reports $8.32B bitcoin loss and sells BTC to fund dividends
- UK budget airline easyJet ready to accept $7.3 billion takeover bid from Castlelake
Amgen Reports Second Quarter 2019 Financial Results
July 30, 2019 4:01 PM EDTTHOUSAND OAKS, Calif., July 30, 2019 /PRNewswire/ --Â Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2019. Key results include:
Total revenues decreased 3% to $5.9 billion in comparison to the second quarter of 2018 reflecting increasing competition due to patent expirations. Product sales declined 2% globally. Prolia® (denosumab), Repatha® (evolocumab), Parsabiv® (etelcalcitide) and Aimovig® (erenumab-aooe) units grew double-digits or better.GAAP earnings per share (EPS) increased 3% to $3.57 benefited by lower weighted-average shares outstanding. GAAP operating income decreased 5% to $2.7 billion and GAAP operating margin decreased 1.9 percentage... More